Skip to main content
. 2021 Dec 27;49(6):2010–2022. doi: 10.1007/s00259-021-05610-x

Fig. 4.

Fig. 4

Kaplan–Meier survival estimates of patients with or without a total lesion glycolysis (TLG)–based primary tumour metabolic response. a Time to progression (TTP) since surgery of patients with a ≥ 12.5% decrease in TLG at primary tumour site (green) from baseline to on-treatment and patients without a ≥ 12.5% decrease (red). Only patients who underwent surgery are included here. b Overall survival since the start of ICB, for the same TLG-based metabolic response groups. The 2 patients who did not undergo surgery are included here. The deceased patients with a TLG-based metabolic response all died disease-free of causes unrelated to HNSCC. P-values were calculated using a log-rank test